[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349701-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349701-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","non-coding-rnas-as-key-regulators-of-interferon-signaling-in-cancer-immunotherapy-mechanistic-insights-and-clinical-prospects","Non-Coding RNAs as key regulators of interferon signaling in cancer immunotherapy: mechanistic insights and clinical prospects","","Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), play vital, context-specific roles in cancer, acting as tumor suppressors or oncogenic factors. Evidence suggests a primary mechanism involves modulation of the interferon (IFN) signaling pathway, shaping immune surveillance and immunotherapy outcomes. Types I, II, and III IFNs regulate antitumor immunity, antigen presentation, and immune checkpoint activity, yet can also support tumor growth. ncRNAs influence IFN signaling by targeting receptors, JAK–STAT components, ISGs, and IRFs. Some ncRNAs may enhance responses to IFN-based therapies, while others may dampen immunity, drive resistance, or promote metastasis. The review addresses mechanistic and translational challenges before clinical application.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/non-coding-rnas-as-key-regulators-of-interferon-signaling-in-cancer-immunotherapy-mechanistic-insights-and-clinical-prospects/349701/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/non-coding-rnas-as-key-regulators-of-interferon-signaling-in-cancer-immunotherapy-mechanistic-insights-and-clinical-prospects/349701.png","ImageObject",300,407,{"name":42,"@type":43},"Himbo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Which interferon signaling components do non-coding RNAs target in cancer immunotherapy?","Question",{"text":63,"@type":64},"The review states that ncRNAs modulate IFN signaling by targeting IFN receptors, JAK–STAT components, interferon-stimulated genes (ISGs), and IRFs, thereby influencing downstream immune effects.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How can ncRNAs both enhance and impair antitumor immunity?",{"text":68,"@type":64},"Some ncRNAs are described as potentially enhancing antitumor immune responses and improving IFN-based therapy outcomes, while others can dampen immune activity, contribute to therapy resistance, or promote metastasis.",{"name":70,"@type":61,"acceptedAnswer":71},"What major barriers limit translating ncRNA–IFN findings into clinical use?",{"text":72,"@type":64},"The review highlights functional complexity, delivery barriers, and off-target effects, alongside limited understanding of specific ncRNA interactions with IFN pathway components and the need for multi-omics validation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349701,1790156796,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":113,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","Clinical and Experimental Medicine (2026) 26:101  \n[https://doi.org/10.1007/s10238-025-02027-w](https://doi.org/10.1007/s10238-025-02027-w)  \nREVIEW  \nNon-Coding RNAs as key regulators of interferon signaling in cancer immunotherapy: mechanistic insights and clinical prospects  \nUsamah Sayed1 · Waleed K. Abdulsahib2 · S. Renuka Jyothi3 · Priya Priyadarshini Nayak4 · Ashish Singh Chauhan5 · Siya Singla6 · Djamila Polatova7 · Fadhil Faez Sead8,9 · Reza Akhavan-Sigari10,11  \nReceived: 29 November 2025 / Accepted: 24 December 2025 © The Author(s) 2025  \nAbstract  \nNon-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), play vital, context-specific roles in cancer, functioning as either tumor suppressors or oncogenic factors. Preliminary evidence suggests that a primary mechanism of ncRNA influence is through the interferon (IFN) signaling pathway, with a focus on how they may regulate IFN-induced immune surveillance and immunotherapy outcomes. Types I, II, and III IFNs regulate antitumor immunity, antigen presentation, and immune checkpoint activity, but can also support tumor growth in certain scenarios. Evidence indicates ncRNAs modulate IFN signaling by targeting IFN receptors, JAK–STAT components, interferon-stimulated genes (ISGs), and IRFs. Some ncRNAs suggest potential to enhance antitumor immune responses and improve responses to IFN-based therapies, while others may dampen immune activity, contribute to therapy resistance, or promote metastasis. This review centers on how ncRNAs act as tumor suppressors or promoters through modulating IFN signaling to influence immunotherapy efficacy, demonstrating their versatile roles in shaping immune surveillance across various cancers. Although encouraging, experimental findings face challenges like functional complexity, delivery barriers, and off-target effects that must be addressed before clinical application. By integrating mechanistic and translational perspectives, this review highlights potential new opportunities to target ncRNA–IFN interactions for personalized medicine and advanced immunotherapies.  \nKeywords Non-coding RNAs · Interferon · Cancer immunotherapy · MicroRNAs  \nIntroduction  \nThe discovery and analysis of non-coding RNAs (ncRNAs)—including microRNAs (miRNAs), long noncoding RNAs (lncRNAs), circular RNAs (circRNAs), and PIWI-interacting RNAs (piRNAs)—have significantly advanced our understanding of gene regulation in cancer research [1–5] . Once thought to be transcriptional noise, these molecules are now recognized as crucial regulators of vital cellular processes, including proliferation, apoptosis, immune modulation, and therapeutic response [5–10] . Among the signaling pathways influenced by ncRNAs, the interferon (IFN) pathway stands out for its central role in coordinating antitumor immunity and its impact on clinical outcomes across various cancers.  \nExtended author information available on the last page of the article  \nInterferons are versatile cytokines classified into three types: I (IFN-α/β), II (IFN-γ), and III (IFN-λ) . They influence biological processes via the JAK-STAT pathway, which activates interferon-stimulated genes (ISGs) [11] . These ISGs play essential roles in the cancer-immunity cycle, including antigen presentation, immune cell infiltration, tumor cell death, and immunological memory formation [12, 13] . However, the role of IFNs in cancer varies significantly by context: short-term activation can enhance immune surveillance and inhibit tumor growth, whereas prolonged or dysregulated IFN signaling can promote immunosuppressive mechanisms. This includes increased expression of immune checkpoint molecules such as PD-L1, allowing tumors to evade immune attack and develop resistance to immunotherapy [12, 14–16] .  \n1 3  \nRecent advances highlight the vital roles of ncRNAs in controlling IFN signaling at multiple stages—both before and after the traditional JAK-STAT pathway. F","cbCaidUK5H59OmKJ","https://ap.wps.com/l/cbCaidUK5H59OmKJ","pdf",2231038,"English","# Abstract\n# Introduction\n## Interferons and the JAK–STAT pathway\n## ncRNAs regulating IFN signaling at multiple stages\n## Challenges and future directions","[{\"question\":\"Which interferon signaling components do non-coding RNAs target in cancer immunotherapy?\",\"answer\":\"The review states that ncRNAs modulate IFN signaling by targeting IFN receptors, JAK–STAT components, interferon-stimulated genes (ISGs), and IRFs, thereby influencing downstream immune effects.\"},{\"question\":\"How can ncRNAs both enhance and impair antitumor immunity?\",\"answer\":\"Some ncRNAs are described as potentially enhancing antitumor immune responses and improving IFN-based therapy outcomes, while others can dampen immune activity, contribute to therapy resistance, or promote metastasis.\"},{\"question\":\"What major barriers limit translating ncRNA–IFN findings into clinical use?\",\"answer\":\"The review highlights functional complexity, delivery barriers, and off-target effects, alongside limited understanding of specific ncRNA interactions with IFN pathway components and the need for multi-omics validation.\"}]","Non-Coding RNAs as key regulators of interferon signaling in cancer immunotherapy: mechanistic insights and clinical prospects | PDF",1790085117,76,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7093d2fb4a02b77f385b83b303da7104.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2af536e8c8c6272d93c419c6ac6caac4.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5693ab45013abe08096f718eb9d28310.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d8ad4d55c4d0e33466b76ad368ca0ad.webp",980,1301]